



**P.17019/01/2019-PvPI**  
**Indian Pharmacopoeia Commission**  
**National Coordination Centre-Pharmacovigilance Programme of India**  
**(Ministry of Health & Family Welfare, Govt. of India)**

**Sector-23, Rajnagar,**  
**Ghaziabad-201002, U.P**  
**Dated: May 15, 2019**

**Monthly Drugs Safety Alerts**

The preliminary analysis of Adverse Drugs Reactions from the PvPI database reveals that the following drug is associated with the risk as given below.

**Table**

<b>Sl. No</b>	<b>Suspected Drugs</b>	<b>Indication</b>	<b>Adverse Drugs Reactions</b>
1	Amiodarone	In the treatment of control of ventricular and supraventricular arrhythmia where other drug cannot be used, arrhythmia associated with wolf-white syndrome.  For cardiopulmonary resuscitation in the event of cardiac arrest related to ventricular fibrillation resistant to external electric shock.	Acute Pancreatitis
2	Teicoplanin	Glycopeptide antibiotic-use in serious gram +ve infection, staphylococcal infection in patients sensitive or unresponsive to penicillin and cephalsporins CAPD related peritonitis, prophylaxis in ortho paedic surgery at risk of gram +ve infections.	Red Man syndrome

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADRs associated with the use of above drugs. If such reactions are encountered, please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. 1800-180-3024.